drugset / Trial / NCT06241846
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, phase II study of YL201 in China to evaluate the efficacy, safety, and PK characteristics of YL201 on mCRPC.
Timeline
- Start
- 2024-02-22
- Primary completion
- 2027-02
- Completion
- 2029-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | YL201 | Other / unclassified | 1 mg/kg | Intravenous |
| Subject | YL201 | Other / unclassified | 1.2 mg/kg | Intravenous |
| Subject | YL201 | Other / unclassified | 1.6 mg/kg | Intravenous |
| Subject | YL201 | Other / unclassified | 2 mg/kg | Intravenous |
| Subject | YL201 | Other / unclassified | 2.4 mg/kg | Intravenous |